Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the ...
Medscape

New Antibody Therapy Shows Promise in Preventing Gout Flares

In a phase 2 trial, firsekibart — an IL-1 beta antibody — outperforms colchicine in preventing acute gout flares over 12 ...

Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot

Eisai files for Japan approval of a weekly at-home Leqembi injection, offering an alternative to IV dosing and aiming to ...
CURE

The Sub-Q Therapy That Cut Hours Off Treatment Time

In 2020, Darzalex Faspro (the Sub-Q version) changed the game. The infusion time went from three hours (or an hour and a half ...
The American Journal of Managed Care

Staffing and Scheduling for Subcutaneous

Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...
The American Journal of Managed Care

Subcutaneous Value: Efficiency and Access

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

The JS001sc-002-III-NSCLC Study is a multi-center, open-label, randomized Phase 3 clinical study led by the principal investigator Professor Lin WU from Hunan Cancer Hospital. JS001sc-002-III-NSCLC is ...
Contract Pharma

EC Approves Subcutaneous Administration of Keytruda

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...